Amryt Pharma is focused on acquiring, developing and commercialising products to treat rare and orphan diseases or expanding their life cycle indications.
Since being founded in 2015, Amryt Pharma has been highly transactional, acquiring two companies and acquiring commercialisation rights to an EU-approved therapeutic for Homozygous Familial Hypercholesterolemia. Five new distribution agreements signed since November 2017 have significantly broadened potential sales.
We remain focused on building-out our portfolio by in-licensing or acquiring innovative products to improve the lives of people living with rare and orphan diseases.
While we continue to focus on our core territories, we also look to partner our products with companies in the Asia Pacific region.
Please contact us at BD@amrytpharma.com with potential opportunities for Amryt Pharma to in-license or acquire orphan/rare disease products or if you are interested in licensing our products in non-core territories.